Harrow has announced an initiative to expand access and affordability for its ophthalmic pharmaceutical products. This includes a program of targeted price reductions for several Harrow products and a ...

The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial. OPUVIZ is a biosimilar ...

ARVN001 is indicated for the treatment of uveitic macular edema (UME) and certain other ophthalmic indications under development. Arctic Vision has signed a new commercial collaboration agreement with ...

Gregg T. Kokame, MD, MMM, FASRS, is set to share data from a predefined subgroup of the sozinibercept Phase 2b wet AMD trial related to patients with polypoidal choroidal vasculopathy (PCV), measured ...

LUNA is an ongoing double-masked, randomized Phase 2 trial. OPTIC is an ongoing, open-label, dose-ranging first-in-human trial. Laurent Fischer, MD, president and chief executive officer of Adverum ...

The FDA comments in the CRL relate to proposed labelling language, not safety, Astellas said in a press release.

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio.

A program from National Health Service (NHS) England will bring optical coherence tomography (OCT) scans “closer to home” for thousands of patients. As part of an effort to improve outcomes for ...

This year’s Barcelona meeting brought together award-winning research findings and leaders in the retina field. Ian C. Han, MD, shares his thoughts on the value of anecdotal evidence in our winter ...

AlloVir, Inc. has entered into a definitive merger agreement to combine with Kalaris Therapeutics in an all-stock transaction. Under the terms of the agreement, AlloVir will acquire 100% of the ...